NO993274L - Behandling av lupus nephritis med anti-CD40L-forbindelser - Google Patents

Behandling av lupus nephritis med anti-CD40L-forbindelser

Info

Publication number
NO993274L
NO993274L NO993274A NO993274A NO993274L NO 993274 L NO993274 L NO 993274L NO 993274 A NO993274 A NO 993274A NO 993274 A NO993274 A NO 993274A NO 993274 L NO993274 L NO 993274L
Authority
NO
Norway
Prior art keywords
treatment
lupus nephritis
cd40l compounds
cd40l
compounds
Prior art date
Application number
NO993274A
Other languages
English (en)
Norwegian (no)
Other versions
NO993274D0 (no
Inventor
Susan L Kalled
David W Thomas
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of NO993274D0 publication Critical patent/NO993274D0/no
Publication of NO993274L publication Critical patent/NO993274L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO993274A 1997-01-10 1999-07-01 Behandling av lupus nephritis med anti-CD40L-forbindelser NO993274L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3467397P 1997-01-10 1997-01-10
PCT/US1997/023482 WO1998030240A1 (en) 1997-01-10 1997-12-31 Treatment of lupus nephritis with anti-cd40l compounds

Publications (2)

Publication Number Publication Date
NO993274D0 NO993274D0 (no) 1999-07-01
NO993274L true NO993274L (no) 1999-09-10

Family

ID=21877889

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993274A NO993274L (no) 1997-01-10 1999-07-01 Behandling av lupus nephritis med anti-CD40L-forbindelser

Country Status (19)

Country Link
US (2) US20030031668A1 (cs)
EP (2) EP1357131A3 (cs)
JP (1) JP2001508441A (cs)
KR (2) KR20000070034A (cs)
CN (2) CN1572325A (cs)
AU (1) AU5709798A (cs)
BR (1) BR9714523A (cs)
CA (1) CA2277222A1 (cs)
CZ (1) CZ297680B6 (cs)
EA (2) EA006314B1 (cs)
EE (1) EE9900273A (cs)
HU (1) HUP0000833A3 (cs)
IL (1) IL130784A0 (cs)
IS (1) IS5100A (cs)
NO (1) NO993274L (cs)
NZ (1) NZ337072A (cs)
PL (1) PL190663B1 (cs)
TR (7) TR200001247T2 (cs)
WO (1) WO1998030240A1 (cs)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
CA2089229C (en) 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
JP2002510643A (ja) * 1998-04-03 2002-04-09 トラスティーズ・オブ・ダートマス・カレッジ 狼瘡およびその関連腎臓疾患の治療および／または後退のための抗−ｇｐ３９抗体の使用
IL126681A0 (en) * 1998-10-21 1999-08-17 Opperbas Holding Bv Treatment of trauma-related conditions
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
ES2277460T3 (es) 1998-12-14 2007-07-01 Genetics Institute, Llc Cadena del receptor de la citoquina.
US6171795B1 (en) * 1999-07-29 2001-01-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to CD40ligand
US20010055593A1 (en) * 2000-03-14 2001-12-27 Joseph Sypek Use of rapamycin and agents that inhibit B7 activity in immunomodulation
AU8867501A (en) * 2000-09-01 2002-03-13 Biogen Inc Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
US20020058029A1 (en) * 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
SG10201404273QA (en) 2003-12-23 2014-10-30 Genentech Inc Novel anti-il 13 antibodies and uses thereof
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
CN100369932C (zh) * 2005-04-07 2008-02-20 苏州大学 抗人cd154单克隆抗体及其应用
DK2367849T3 (en) * 2008-12-05 2018-01-22 Als Therapy Development Inst METHOD OF TREATING NEURODEGENERATIVE DISEASES
US9044459B2 (en) 2008-12-05 2015-06-02 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
WO2012031122A2 (en) * 2010-09-03 2012-03-08 Immport Therapeutics, Inc. Methods and compositions for the diagnosis and treatment of cancer and autoimmune disorders
CA2920686C (en) 2013-09-13 2022-12-06 Genentech, Inc. Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
IL320195A (en) 2013-09-13 2025-06-01 Genentech Inc Methods and compositions containing purified recombinant polypeptides
EP3191131A4 (en) 2014-08-21 2018-09-05 The General Hospital Corporation Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
US20180251559A1 (en) * 2015-08-31 2018-09-06 Julie DeMartino Methods for the Modulation of LGALS3BP to Treat Systemic Lupus Erythematosus
AU2018271915B2 (en) 2017-05-24 2025-03-27 Als Therapy Development Institute Therapeutic anti-CD40 ligand antibodies
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
CA3209479A1 (en) 2021-02-03 2022-08-11 Mozart Therapeutics, Inc. Binding agents and methods of using the same
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
JP2000503659A (ja) * 1996-01-16 2000-03-28 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティー オブ ニューヨーク 自己抗体の沈着以外の開始点を有する炎症性腎疾患を処置するためのｔ―ｂａｍ（ｃｄ４０―ｌ）技術の治療的適用
WO1997034473A1 (en) * 1996-03-21 1997-09-25 The Trustees Of Columbia University In The City Of New York Craf1 (traf-3) isoforms and uses thereof

Also Published As

Publication number Publication date
HUP0000833A2 (en) 2000-07-28
IL130784A0 (en) 2001-01-28
EP1357131A2 (en) 2003-10-29
KR100618081B1 (ko) 2006-08-30
TR200001251T2 (tr) 2000-09-21
EA200501076A1 (ru) 2006-06-30
CN1572325A (zh) 2005-02-02
US20070190053A1 (en) 2007-08-16
BR9714523A (pt) 2000-05-02
JP2001508441A (ja) 2001-06-26
EA199900636A1 (ru) 2000-02-28
CZ244499A3 (cs) 1999-10-13
CZ297680B6 (cs) 2007-03-07
TR200001250T2 (tr) 2001-03-21
HUP0000833A3 (en) 2001-09-28
TR200001247T2 (tr) 2002-06-21
US20030031668A1 (en) 2003-02-13
TR200001246T2 (tr) 2000-07-21
AU5709798A (en) 1998-08-03
EA006314B1 (ru) 2005-10-27
KR20000070034A (ko) 2000-11-25
PL334495A1 (en) 2000-02-28
CA2277222A1 (en) 1998-07-16
IS5100A (is) 1999-06-30
WO1998030240A1 (en) 1998-07-16
EP1357131A3 (en) 2004-02-11
EP0948355A1 (en) 1999-10-13
KR20050089165A (ko) 2005-09-07
TR199902191T2 (xx) 1999-12-21
CN1247472A (zh) 2000-03-15
PL190663B1 (pl) 2005-12-30
TR200001248T2 (tr) 2000-07-21
EE9900273A (et) 2000-02-15
NZ337072A (en) 2000-12-22
NO993274D0 (no) 1999-07-01
TR200001249T2 (tr) 2000-11-21

Similar Documents

Publication Publication Date Title
NO993274D0 (no) Behandling av lupus nephritis med anti-CD40L-forbindelser
ID24372A (id) SENYAWA-SENYAWA 4-AMINO-TIAZOL-2-IL SEBAGAI PENGHAMBAT-PENGHAMBAT CDKs
DK0861081T3 (da) Anvendelse af epinastin til behandling af smerter
ID24638A (id) Senyawa-senyawa anti aritmia bispidina
NO20012995L (no) Forbindelser nyttige for behandling av inflammatoriske sykdommer
NO20001479L (no) Behandling av atferdsforstyrrelse
NO20003065L (no) Kombinasjon for effektiv behandling av impotens
NO20011083L (no) Krystallinske former av EtOC2--CH2-(R)Cgl-Aze-Pab-OH
NO20001847L (no) Ny anvendelse av forbindelser for anti-kløe-aktivitet
IS4789A (is) Meðferðarefnasambönd
NO996545D0 (no) Behandling av aluminiumslagg
DK1008558T3 (da) Fremgangsmåde til behandling af organisk spildevand
GB9701674D0 (en) Use of organic compounds
DE69433141D1 (de) Zusammensetzungen aus kohleteerschlamm
ID17424A (id) Penghambat matriks metaloproteasa oleh senyawa-senyawa fenetil tersubstitusi
NO20010390D0 (no) Behandling av angstsykdommer
NO982562D0 (no) Sammensetning for behandling av smerte
NO993549D0 (no) Imino-aza-antracyklinonderivater til behandling av amyloidosis
NO20002481D0 (no) Kombinasjonsterapi for behandling av AIDS
NO20003529D0 (no) Behandling av dyskinesi
NO20022244D0 (no) Behandling av SLE med dehydroepiandrosteron
PT1175417E (pt) Compostos substituidos de benzolactamas
HK1025041A (en) Treatment of lupus nephritis with anti-cd40l compounds
FI963617A0 (fi) Ei-toivottujen halogenoitujen orgaanisten yhdisteiden käsittely
HK1023068A (en) Treatment of iupus nephritis with anti-cd40l compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application